EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Cited by (154)

Items 101–154 of 154

1. EGFR-mutated lung cancer: a paradigm of molecular oncology
   Zhang, Zhenfeng, Stiegler, Amy L., Boggon, Titus J., Kobayashi, Susumu, Halmos, Balazs · 2010 · Oncotarget
2. Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view
   Lu, Shaoyong, Jang, Hyunbum, Gu, Shuo, Zhang, Jian, Nussinov, Ruth · 2016 · Chemical Society Reviews
3. Epidermal Growth Factor Receptor Mutants from Human Lung Cancers Exhibit Enhanced Catalytic Activity and Increased Sensitivity to Gefitinib
   Mulloy, Roseann, Ferrand, Audrey, Kim, Youngjoo, Sordella, Raffaella, Bell, Daphne W., Haber, Daniel A., Anderson, Karen S., Settleman, Jeffrey · 2007 · Cancer Research
4. Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor: Comparison between T790M mutation‐positive and mutation‐negative populations
   Hata, Akito, Katakami, Nobuyuki, Yoshioka, Hiroshige, Takeshita, Jumpei, Tanaka, Kosuke, Nanjo, Shigeki, Fujita, Shiro, Kaji, Reiko, Imai, Yukihiro, Monden, Kazuya et al. · 2013 · Cancer
5. Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence
   Ou, Sai-Hong Ignatius · 2012 · Critical Reviews in Oncology/Hematology
6. A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components
   Nilsson, Monique B., Sun, Huiying, Robichaux, Jacqulyne, Pfeifer, Matthias, McDermott, Ultan, Travers, Jon, Diao, Lixia, Xi, Yuanxin, Tong, Pan, Shen, Li et al. · 2020 · Science Translational Medicine
7. Patients with Exon 19 Deletion Were Associated with Longer Progression-Free Survival Compared to Those with L858R Mutation after First-Line EGFR-TKIs for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
   Zhang, Yaxiong, Sheng, Jin, Kang, Shiyang, Fang, Wenfeng, Yan, Yue, Hu, Zhihuang, Hong, Shaodong, Wu, Xuan, Qin, Tao, Liang, Wenhua et al. · 2014 · PLoS ONE
8. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer.
   Su, Zengliu, Dias-Santagata, Dora, Duke, MarKeesa, Hutchinson, Katherine, Lin, Ya-Lun, Borger, Darrell R., Chung, Christine H., Massion, Pierre P., Vnencak-Jones, Cindy L., Iafrate, A. John et al. · 2011 · The Journal of Molecular Diagnostics
9. Effects of Erlotinib in <i>EGFR</i> Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib
   Costa, Daniel B., Nguyen, Kim-Son H., Cho, Byoung C., Sequist, Lecia V., Jackman, David M., Riely, Gregory J., Yeap, Beow Y., Halmos, Balázs, Kim, Joo H., Jänne, Pasi A. et al. · 2008 · Clinical Cancer Research
10. Functional Analysis of Epidermal Growth Factor Receptor (EGFR) Mutations and Potential Implications for EGFR Targeted Therapy
    Kancha, Rama Krishna, von Bubnoff, Nikolas, Peschel, Christian, Duyster, Justus · 2009 · Clinical Cancer Research
11. Advances in the preclinical testing of cancer therapeutic hypotheses
    Caponigro, Giordano, Sellers, William R. · 2011 · Nature Reviews Drug Discovery
12. Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips
    Earhart, Christopher M., Hughes, Casey E., Gaster, Richard S., Ooi, Chin Chun, Wilson, Robert J., Zhou, Lisa Y., Humke, Eric W., Xu, Lingyun, Wong, Dawson J., Willingham, Stephen B. et al. · 2014 · Lab Chip
13. Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial
    Yang, James Chih-Hsin, Camidge, D. Ross, Yang, Cheng-Ta, Zhou, Jianying, Guo, Renhua, Chiu, Chao-Hua, Chang, Gee-Chen, Shiah, Her-Shyong, Chen, Yuan, Wang, Chin-Chou et al. · 2020 · Journal of Thoracic Oncology
14. <i>In vitro</i> modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant <i>EGFR</i> mutants in non-small-cell lung cancer
    Hirano, Toshiyuki, Yasuda, Hiroyuki, Tani, Tetsuo, Hamamoto, Junko, Oashi, Ayano, Ishioka, Kota, Arai, Daisuke, Nukaga, Shigenari, Miyawaki, Masayoshi, Kawada, Ichiro et al. · 2015 · Oncotarget
15. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers
    Costa, Daniel B., Kobayashi, Susumu, Tenen, Daniel G., Huberman, Mark S. · 2007 · Lung Cancer
16. Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas
    Cortot, Alexis B., Jänne, Pasi A. · 2014 · European Respiratory Review
17. Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers
    Nilsson, Monique B., Sun, Huiying, Diao, Lixia, Tong, Pan, Liu, Diane, Li, Lerong, Fan, Youhong, Poteete, Alissa, Lim, Seung-Oe, Howells, Kathryn et al. · 2017 · Science Translational Medicine
18. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations
    Yamamoto, Chizuko, Basaki, Yuji, Kawahara, Akihiko, Nakashima, Kazutaka, Kage, Masayoshi, Izumi, Hiroto, Kohno, Kimitoshi, Uramoto, Hidetaka, Yasumoto, Kosei, Kuwano, Michihiko et al. · 2010 · Cancer Research
19. Co-delivery of oxygen and erlotinib by aptamer-modified liposomal complexes to reverse hypoxia-induced drug resistance in lung cancer
    Li, Fengqiao, Mei, Hao, Gao, Yu, Xie, Xiaodong, Nie, Huifang, Li, Tao, Zhang, Huijuan, Jia, Lee · 2017 · Biomaterials
20. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors
    Jänne, Pasi A., Johnson, Bruce E. · 2006 · Clinical Cancer Research
21. Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Blockade Is an Effective Radiosensitizing Strategy for the Treatment of Non–Small Cell Lung Cancer Harboring <i>K-RAS</i> Mutations
    Konstantinidou, Georgia, Bey, Erik A., Rabellino, Andrea, Schuster, Katja, Maira, Michael S., Gazdar, Adi F., Amici, Augusto, Boothman, David A., Scaglioni, Pier Paolo · 2009 · Cancer Research
22. Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor
    Yoshikawa, S, Kukimoto-Niino, M, Parker, L, Handa, N, Terada, T, Fujimoto, T, Terazawa, Y, Wakiyama, M, Sato, M, Sano, S et al. · 2013 · Oncogene
23. Battling Btk mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations
    Johnson, Adam R., Kohli, Pawan Bir, Katewa, Arna, Gogol, Emily, Belmont, Lisa D., Choy, Regina, Penuel, Elicia, Burton, Luciana, Eigenbrot, Charles, Yu, Christine et al. · 2016 · ACS Chemical Biology
24. Afatinib restrains K-RAS–driven lung tumorigenesis
    Moll, Herwig P., Pranz, Klemens, Musteanu, Monica, Grabner, Beatrice, Hruschka, Natascha, Mohrherr, Julian, Aigner, Petra, Stiedl, Patricia, Brcic, Luka, Laszlo, Viktoria et al. · 2018 · Science Translational Medicine
25. Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization
    Cho, Jeonghee, Chen, Liang, Sangji, Naveen, Okabe, Takafumi, Yonesaka, Kimio, Francis, Joshua M., Flavin, Richard J., Johnson, William, Kwon, Jihyun, Yu, Soyoung et al. · 2013 · Cancer Research
26. Finding the tumor copycat: Therapy fails, patients don’t
    Ellis, Lee M, Fidler, Isaiah J · 2010 · Nature Medicine
27. Uncommon Epidermal Growth Factor Receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance
    Massarelli, Erminia, Johnson, Faye M., Erickson, Heidi S., Wistuba, Ignacio I., Papadimitrakopoulou, Vassiliki · 2013 · Lung Cancer
28. Targeting EGFR in Lung Cancer: Current Standards and Developments
    Díaz-Serrano, Asunción, Gella, Pablo, Jiménez, Elisabeth, Zugazagoitia, Jon, Paz-Ares Rodríguez, Luis · 2018 · Drugs
29. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer
    Tan, Chee-Seng, Cho, Byoung-Chul, Soo, Ross A. · 2016 · Lung Cancer
30. Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
    Neel, Dana S., Bivona, Trever G. · 2017 · npj Precision Oncology
31. Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
    Arasada, Rajeswara Rao, Shilo, Konstantin, Yamada, Tadaaki, Zhang, Jianying, Yano, Seiji, Ghanem, Rashelle, Wang, Walter, Takeuchi, Shinji, Fukuda, Koji, Katakami, Nobuyuki et al. · 2018 · Nature Communications
32. Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
    Lee, Ho-June, Schaefer, Gabriele, Heffron, Timothy P., Shao, Lily, Ye, Xiaofen, Sideris, Steve, Malek, Shiva, Chan, Emily, Merchant, Mark, La, Hank et al. · 2013 · Cancer Discovery
33. AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients
    Xu, Xiao, Mao, Long, Xu, Wanhong, Tang, Wei, Zhang, Xiaoying, Xi, Biao, Xu, Rongda, Fang, Xin, Liu, Jia, Fang, Ce et al. · 2016 · Molecular Cancer Therapeutics
34. Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors
    Yuza, Yuki, Glatt, Karen A., Jiang, Jingrui, Greulich, Heidi, Minami, Yuko, Woo, Michele S., Shimamura, Takeshi, Shapiro, Geoffrey I., Lee, Jeffrey C., Ji, Hongbin et al. · 2007 · Cancer Biology &amp; Therapy
35. Opportunities and challenges in combination gene cancer therapy
    Nastiuk, Kent L., Krolewski, John J. · 2016 · Advanced Drug Delivery Reviews
36. High T790M detection rate in TKI-naive NSCLC with EGFR sensitive mutation: truth or artifact?
    Ye, Xin, Zhu, Zhong-Zheng, Zhong, Lei, Lu, Yachao, Sun, Yun, Yin, Xiaolu, Yang, Zhenfan, Zhu, Guanshan, Ji, Qunsheng · 2013 · Journal of Thoracic Oncology
37. Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
    Tang, Daolin, Kroemer, Guido, Kang, Rui · 2021 · Molecular Cancer
38. Genome-wide CRISPR screening reveals genetic modifiers of mutant EGFR dependence in human NSCLC
    Zeng, Hao, Castillo-Cabrera, Johnny, Manser, Mika, Lu, Bo, Yang, Zinger, Strande, Vaik, Begue, Damien, Zamponi, Raffaella, Qiu, Shumei, Sigoillot, Frederic et al. · 2019 · eLife
39. Toward a More Precise Future for Oncology
    Murciano-Goroff, Yonina R., Taylor, Barry S., Hyman, David M., Schram, Alison M. · 2020 · Cancer Cell
40. Molecular pathways: sensitivity and resistance to anti-EGFR antibodies
    Bertotti, Andrea, Sassi, Francesco · 2015 · Clinical Cancer Research
41. EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models
    Venugopalan, Abhilash, Lee, Min-Jung, Niu, Gang, Medina-Echeverz, José, Tomita, Yusuke, Lizak, Martin J., Cultraro, Constance M., Simpson, Robert Mark, Chen, Xiaoyuan, Trepel, Jane B. et al. · 2016 · Oncotarget
42. A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors
    Zhang, Jian, Cao, Junning, Li, Jin, Zhang, Yifan, Chen, Zhiyu, Peng, Wei, Sun, Si, Zhao, Naiqing, Wang, Jiachen, Zhong, Dafang et al. · 2014 · Journal of Hematology &amp; Oncology
43. Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer
    Yap, Timothy A., Macklin-Doherty, Aislinn, Popat, Sanjay · 2017 · European Journal of Cancer
44. Recent advances in the development of RIPK2 modulators for the treatment of inflammatory diseases
    Pham, Anh-Tuan, Ghilardi, Amanda Franceschini, Sun, Lijun · 2023 · Frontiers in Pharmacology
45. Combining Erlotinib and Cetuximab Is Associated with Activity in Patients with Non–Small Cell Lung Cancer (Including Squamous Cell Carcinomas) and Wild-Type<i>EGFR</i>or Resistant Mutations
    Wheler, Jennifer J., Tsimberidou, Apostolia M., Falchook, Gerald S., Zinner, Ralph G., Hong, David S., Fok, Jansina Y., Fu, Siqing, Piha-Paul, Sarina A., Naing, Aung, Kurzrock, Razelle · 2013 · Molecular Cancer Therapeutics
46. SH-1028, An Irreversible Third-Generation EGFR TKI, Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer
    Han, Luwei, Zhang, Xiaomeng, Wang, Zhiqiang, Zhang, Xian, Zhao, Liwen, Fu, Wei, Liang, Xiaobo, Zhang, Zhibo, Wang, Yong · 2021 · Frontiers in Pharmacology
47. BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations
    Cardona, Andrés F., on behalf of the CLICaP, Rojas, Leonardo, Wills, Beatriz, Arrieta, Oscar, Carranza, Hernán, Vargas, Carlos, Otero, Jorge, Corrales-Rodriguez, Luis, Martín, Claudio et al. · 2016 · Oncotarget
48. The AhR‐SRC axis as a therapeutic vulnerability in BRAFi‐resistant melanoma
    Paris, Anaïs, Tardif, Nina, Baietti, Francesca M, Berra, Cyrille, Leclair, Héloïse M, Leucci, Eleonora, Galibert, Marie‐Dominique, Corre, Sébastien · 2022 · EMBO Molecular Medicine
49. Dynamic monitoring of EGFR mutations in circulating cell-free DNA for EGFR-mutant metastatic patients with lung cancer: Early detection of drug resistance and prognostic significance
    Ni, Jianjiao, Weng, Linqian, Liu, Yi, Sun, Zhao, Bai, Chunmei, Wang, Yingyi · 2017 · Oncology Letters
50. The origins of cancer cell dormancy
    Morales-Valencia, Jorge, David, Gregory · 2022 · Current Opinion in Genetics &amp; Development
51. Overcoming Resistance to AC0010, a Third Generation of EGFR Inhibitor, by Targeting c-MET and BCL-2
    Xu, Wanhong, Tang, Wei, Li, Tingting, Zhang, Xiaoying, Sun, Yi · 2019 · Neoplasia
52. The status of immunosuppression in patients with stage IIIB or IV non-small-cell lung cancer correlates with the clinical characteristics and response to chemotherapy
    Wang, Yuan, Hu, Guo-fang, Wang, Zhehai · 2017 · OncoTargets and Therapy
53. Clinical activity of <scp>ASP</scp>8273 in Asian patients with non‐small‐cell lung cancer with <scp>EGFR</scp> activating and T790M mutations
    Murakami, Haruyasu, Nokihara, Hiroshi, Hayashi, Hidetoshi, Seto, Takashi, Park, Keunchil, Azuma, Koichi, Tsai, Chun‐Ming, Yang, James Chih‐Hsin, Nishio, Makoto, Kim, Sang‐We et al. · 2018 · Cancer Science
54. Clinical usefulness of gefitinib for non-small-cell lung cancer with a double epidermal growth factor receptor mutation
    OIKAWA, TAKEFUMI, OHIRA, TATSUO, OTANI, KEISHI, HAGIWARA, MASARU, KONAKA, CHIMORI, IKEDA, NORIHIKO · 2015 · Molecular and Clinical Oncology